All In Biotech

Drug Trial Radar · NCT02323217

I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers

I2PETHV - Quantification and Localisation of Imidazoline2 Binding Sites in Healthy Volunteers Using [11C]BU99008 a Positron Emission Tomography Study

Last checked: Nov 20, 2026Latest source record: Nov 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

20

Actual

Start

Jan 2015

Primary completion

Feb 2016

Study completion Jul 2016

Sponsor

Lead sponsor
Imperial College LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GlaxoSmithKline
First posted
Dec 23, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
Who can join
Male only, from 40 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The imdazoline2 binding site (I2BS) is known to reside inside astrocytes. Changes in the numbers of I2BS in post mortem tissue has implicated them in a range of psychiatric conditions such as depression and addiction, along with neurodegenerative disorders such as Alzheimer's disease and Huntington's chorea. Preclinical studies have also demonstrated functional interactions with the opioid system, where I2BS ligands have been shown to affect tolerance to morphine and alleviate some of the morphine withdrawal syndrome in rats. Recently the I2BS and I2BS ligands have been shown to have some interesting analgesic effects in different models of pain and a novel I2BS ligand, CR4056, is currently undergoing Phase II clinical trials as a novel treatment for neuropathic pain and acute non- specific pain states. The location of I2BS on astrocytic glial cells and the possibility that they may in some way regulate glial fibrillary acidic protein have led to increased interest into the role of I2BS and I2BS ligands in conditions characterised by marked gliosis. The number of I2BS has been shown to increase in Alzheimer's disease post mortem, and it has also been suggested that I2BS may be a marker for the severity and malignancy of human glioblastomas. The lack of suitable imaging tools for the I2BS has meant that information regarding the number and distribution of I2BS in the brain has come from preclinical species and in vitro post-mortem studies. The recent development of \[11C\]BU99008 as a suitable PET ligand to quantify I2BS in vivo, enables the direct quantification of I2BS availability and regional distribution in the living human brain. In this study the investigators plan to utilise \[11C\]BU99008 to quantify the regional brain availability of I2BS in the human brain in vivo using PET.

Conditions

  • Healthy Volunteers
  • Alzheimer Disease
  • Molecular Imaging

Interventions

  • [11C]BU99008Radiation

    Baseline Scan, Test-ReTest or Dosimetry

  • IdazoxanDrug

    Idazoxan block of \[11C\]BU99008

  • IsocarboxazidDrug

    Isocarboxazid block of \[11C\]BU99008

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Determination of the Regional Density and Distribution of I2BS in Healthy Human Brain (1TCM Model)Time frame: 1 week
  2. Determination of the Regional Density and Distribution of I2BS in Healthy Human Brain (2TCM Model)Time frame: 1 week
  3. Determination of the Regional Density and Distribution of I2BS in Healthy Human Brain (MA Model)Time frame: 1 week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Neuropsychopharmacology; Division of Brain Sciences; Imperial College London; Burlington Danes Building; Hammersmith Hospital campus; 160 Du Cane Road

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.